Repertoire Immune Medicines

📍 Cambridge, United States🗓 Founded 2020👥 77 employees💰 Last funded 2016
Biotechnology Research🌐 repertoire.com
Website LinkedIn
Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Our proprietary DECODE platform is designed to provide a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Repertoire Immune Medicines?
Repertoire Immune Medicines has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Repertoire Immune Medicines last raise funding?
The most recent investment in Repertoire Immune Medicines recorded on gritt.io was in 2016.
When was Repertoire Immune Medicines founded?
Repertoire Immune Medicines was founded in 2020.
What industry is Repertoire Immune Medicines in?
Repertoire Immune Medicines operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Repertoire Immune Medicines based?
Repertoire Immune Medicines is headquartered in Cambridge, United States.